EN DE
STOCK COMPARISON

Johnson & Johnson vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Johnson & Johnson (JNJ) and Eli Lilly and (LLY) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $278 versus a fair value of $169 (-39%), while Eli Lilly and trades at $1,160 versus $389 (-66%).
Johnson & Johnson
JNJ · USD · Health Care
-39%
upside to fair value
overvalued
Price$278
Fair Value$169
Quality82/100
Eli Lilly and
LLY · USD · Health Care
-66%
upside to fair value
overvalued
Price$1,160
Fair Value$389
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Johnson & JohnsonEli Lilly and
Valuation
29.4×P/E (TTM)42.2×
6.34×P/S (TTM)14.67×
7.49×P/B39.94×
18.4×EV/EBITDA30.2×
4.95×PEG1.54×
−39.3%Fair value upside−66.4%
1.9%Dividend yield0.5%
$5.20Dividend per share$6.23
Profitability
27%Operating margin49%
1.14×EBIT margin trend (5Y)1.42×
26%Return on equity107%
8%Return on assets21%
Growth
10%Revenue growth (YoY)56%
5.6%Avg. growth/yr (3Y)31.7%
2.7%Avg. growth/yr (5Y)21.6%
+15.2%Value creation/yr+29.3%
Balance & size
26.4×Interest coverage (EBIT/interest)37.3×
0.48×Debt / equity1.54×
$611BMarket cap$1.1T
healthyGrowth qualitymixed

Even match: 8 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Johnson & Johnsonof which business quality 76 · market factors 88 Eli Lilly andof which business quality 65 · market factors 78
ProfitabilityMargins and returns on capital today
74
85
Quality GrowthAre margins and returns improving?
73
86
CashflowEarnings quality: real cash, not paper profit
70
51
Fin. StrengthBalance sheet, leverage, solvency risk
72
53
InvestmentDisciplined investing over empire-building
87
15
Low VolatilityCalm price path (market factor)
96
77
MomentumPrice trend over the last 3–12 months (market factor)
75
71
52W MomentumDistance to the 52-week high (market factor)
100
92
Net IssuanceBuybacks instead of dilution
90
93

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyJohnson & JohnsonPrice $278Eli Lilly andPrice $1,160
DCF Models-39%below the price$171-71%below the price$334
Earnings-Based-74%below the price$73.34-79%below the price$239
Dividend Discount-66%below the price$93.41-90%below the price$115
Multiples-42%below the price$163-69%below the price$358
Asset-Based-92%below the price$22.70-98%below the price$19.94
Growth DCF-54%below the price$129-84%below the price$187
Economic Profit-64%below the price$102-70%below the price$347
Growth Earnings-26%below the price$207-68%below the price$375
Minimum-92%below the price$22.70-98%below the price$19.94
Maximum-26%below the price$207-68%below the price$375
Median-59%below the price$115-75%below the price$287
Geometric mean-63%below the price$102-84%below the price$189

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Johnson & Johnson: 26 of 26 models see the stock below the current price.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Johnson & Johnson
Bear $106Fair Value $169Bull $255
$278 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,160 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Johnson & Johnson · Health Care

Quality score82 · Top 25%
Fair value upside-39% · below median

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-66% · bottom 25%

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $278 versus a fair value of $169 (-39%), while Eli Lilly and trades at $1,160 versus $389 (-66%).

Johnson & Johnson has the higher quality score (82/100).

See the full analysis →
Johnson & Johnson · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Johnson & Johnson

Johnson & Johnson vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Eli Lilly and

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.